Home arrow News arrow H1N1 (SWINE) FLU UPDATE - October 26, 2009
H1N1 (SWINE) FLU UPDATE - October 26, 2009 Print E-mail
User Rating: / 0
Post by Administrator   
พฤหัสบดี, 29 ตุลาคม 2009

The H1N1 (swine) flu virus continues to be the dominant influenza virus in circulation worldwide.

In the U.S., through October 26 rates of influenza-like-illness (ILI) continued to increase and remain above seasonal baseline in most regions. Widespread influenza activity was reported by 46 states. The southeast region is now finishing up its peak activity, followed by the central, south-central and west regions. In contrast, activity in the northeast and north-central regions (which include New York City, Washington D.C., Philadelphia, and Chicago) is still increasing.


FROM: Shoreland's Travax Alert Service

* From August 30 to October 17 there were 8,204 hospitalizations and 411
  deaths associated with influenza virus infection reported to CDC. There have
  been approximately 1,000 such deaths since the outbreak began in April 2009.
  (Note: CDC reports 36,000 deaths each year due to seasonal flu.)
* From October 11 to 17, 7.1% of patient visits reported were due to ILI
  nationwide,  ranging from 2.7% to 12.5% in different regions. However, many
  individuals with ILI are not currently seeking medical attention.
* On October 24 President Obama declared H1N1 (swine) flu a national health
  emergency. This allows hospitals to set up off-site facilities to increase
  the number of available beds and to protect patients who are not infected.
  Also, HHS may waive certain requirements under Medicare and Medicaid,
  privacy rules, and other regulations.

In Europe, through October 23, Iceland reported very high intensity, Ireland and the UK (Northern Ireland) reported high intensity ILI and/or acute respiratory illness, and Belgium, Bulgaria, the Netherlands, Spain, and Sweden reported medium intensity. All other countries reported low intensity.

In Canada, from October 11 to 17, the overall influenza activity increased for the fifth consecutive week, with the highest level of activity in British Columbia. The intensity of H1N1 (swine) flu was moderate with 64 hospitalizations and 3 deaths reported. As of October 17, a total of 1,604 hospitalizations and 83 deaths had been reported since the beginning of the pandemic in April 2009.

In the temperate regions of the Southern Hemisphere no significant pandemic-related activity has been reported in the past week.

In the tropical regions of the Americas and Asia rates of illness are generally declining with the exceptions of Cuba, Colombia, and El Salvador reporting increases in ILI.

Of note, the proportion of cases in Asia that are related to seasonal influenza A(H3N2) continue to decline as H1N1 (swine) flu virus increases. Currently, only East Asia is reporting significant numbers of influenza A(H3N2) isolates.

U.S. seasonal flu vaccine: About 70M of 114M total doses have shipped. Most remaining orders are expected to ship by November. Delays appear to be greater than expected, and vaccination campaigns may be affected.

U.S. H1N1 (swine) flu vaccine: Only 16.1 of 45 million doses expected to date have become available for distribution thus far. CDC now predicts 28 million doses by the end of October. Supply has been affected by very low yields, and likely most doses will not be available until early 2010. Supply may be further affected by increased demand for vaccine in Europe due to the recommendation for 2 doses of H1N1 vaccine; see below.

* Although there is not likely to be an adequate supply of H1N1 (swine) flu
  vaccine for the current wave of illness, which is expected to diminish by
  late-November, the possibility of a second wave in early 2010 is
  unpredictable at this point in time.

EU: The Committee for Medicinal Products for Human Use (CHMP) recommends 2 doses of H1N1 (swine) flu vaccine but states that limited data show that 1 dose of GSK's Pandemrix or Novartis' Focetria may be sufficient in adults 18-60 years of age. CHMP is awaiting data for Baxter's Celvepan, a cell-culture vaccine, and recommends 2 doses of the vaccine.

CANADA: The adjuvanted H1N1 (swine) flu vaccine AREPANRIX has been approved (1 dose for persons 10 years and older and 2 half-doses for persons 6 months through 9 years of age), and an unadjuvanted vaccine for use in young children and pregnant women is expected to be licensed in early November. 

FDA issued an Emergency Use Authorization (EUA) for intravenous use of the investigational antiviral drug peramivir (BioCryst Pharmaceuticals) for use in hospitalized persons with severe illness.

Last Updated ( พฤหัสบดี, 29 ตุลาคม 2009 )
< Previous   Next >